Author

Laura Guijarro-López

GlaxoSmithKline (Spain)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:bacteria (other)· 1 Organism:mouse· 1

Frequent Co-Authors

Kevin D. ReadiD· 3 shared Laura A. T. CleghorniD· 3 shared Paul Graham WyattiD· 3 shared Simon R. GreeniD· 3 shared Clifton E. BarryiD· 2 shared Dirk SchnappingeriD· 2 shared Helena I. BoshoffiD· 2 shared Kirsteen I. Buchanan· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Kevin D. ReadORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintOct 27, 2026

DDU384: A new preclinical candidate for the treatment of Tuberculosis

Simon R. Green, Kirsteen I. Buchanan, Helena I. Boshoff…·Laura A. T. Cleghorn

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

DOI 10.64898/2026.10.26.760366

mouseexperimental assay

𝕏 PostBluesky

BiochemistryACS Infectious DiseasesPeer-reviewedMay 14, 2026

Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis

Claire Naylor, Gareth A. Prosser, Tracy Bayliss…·Laura A. T. Cleghorn

The paper identifies and evaluates dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis, showing activity across multiple media and differential sensitivity in resistant strains.

DOI 10.1021/acsinfecdis.6c00123

bacteria (other)experimental assay

𝕏 PostBluesky

MicrobiologyJournal of Medicinal ChemistryPeer-reviewedAug 1, 2025

Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis

Susan H. Davis, Michael Mathieson, Kirsteen I. Buchanan…·Laura A. T. Cleghorn

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

3 citations

experimental assaydrug response / drug discovery

𝕏 PostBluesky